Answer to this three questions for my MD Anaesthesiology exam
Checking Date & Time
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Finding Sources
Reading File
Reading File
Reading File
I now have comprehensive content from Miller's Anesthesia and Barash's Clinical Anesthesia. The image only shows Question 1 fully. I notice the image title says "MAY 24 ANSWER..." which suggests this is an answer document — meaning the user wants me to answer 3 questions but I can only see Question 1 in the image. Let me provide the complete, exam-ready answer for Question 1 based on what was asked.
MAY 24 Paper 1 — Question 1
"What are the various routes of administration of morphine? Mention the doses. Discuss the pharmacokinetics and pharmacodynamics of epidural morphine. [3+3+4]"
Note: The image appears to show only Question 1. Please share the other two questions so I can answer them as well.
A.1 Routes of Administration of Morphine with Doses [3 marks]
Morphine is a hydrophilic phenanthrene opioid acting primarily at μ-opioid receptors. It is administered via multiple routes:
| Route | Dose | Key Features |
|---|---|---|
| Oral (Immediate Release) | 10–30 mg every 4 h | Bioavailability ~30–40% due to extensive first-pass hepatic metabolism |
| Oral (Sustained Release / MST) | 15–60 mg every 12 h | Slow onset (3–5 h); used in chronic cancer pain and palliative care |
| Intravenous (IV) | 2–5 mg slow IV every 4 h; or 0.1 mg/kg | Rapid onset (5–10 min); peak at 15–30 min; titrateable; gold standard for acute/perioperative pain |
| Intramuscular (IM) | 5–10 mg every 4–6 h | Variable absorption; painful; no advantage over IV |
| Subcutaneous (SC) | 5–10 mg every 4–6 h | Slower onset; preferred in palliative/home settings |
| Epidural | 2.5–5 mg bolus; infusion 0.1–0.3 mg/h | Segmental analgesia; onset 30–60 min; long duration (12–24 h) |
| Intrathecal (Spinal) | 0.1–0.5 mg single dose | Very long duration due to hydrophilicity; used in cesarean, orthopedic, cancer pain |
| Rectal | 10–30 mg every 4 h | Bioavailability ~24%; used when oral route unavailable |
| Intranasal | 0.1 mg/kg | Rapid absorption via nasal mucosa; useful in pediatrics |
| Transdermal | Not suitable | Poor skin permeability; fentanyl used instead |
| Extended-release Epidural (DepoDur) | 5–15 mg single dose | DepoFoam technology; provides 24–48 h analgesia; smaller peak plasma concentration vs. plain epidural morphine |
— Miller's Anesthesia 10e, Barash's Clinical Anesthesia 9e
A.2 Pharmacokinetics of Epidural Morphine [3 marks]
Physicochemical Basis
Morphine is highly hydrophilic (low lipid solubility, octanol:water partition coefficient ~1.4 vs. fentanyl's ~860). This single property governs all its epidural pharmacokinetic behaviour.
Steps After Epidural Injection
1. Distribution in the Epidural Space
- Morphine distributes freely in the epidural fat and venous plexus.
- Being hydrophilic, it is poorly taken up by epidural fat, minimising local sequestration.
2. Penetration Through the Dura (Meningeal Permeability)
- Crosses the dura slowly due to low lipid solubility → slow onset of analgesia (30–60 minutes).
- Opioids with intermediate lipophilicity (hydromorphone, meperidine) cross faster; morphine has greatest bioavailability at the spinal cord once it reaches CSF.
3. Distribution in CSF
- Once in CSF, morphine remains in the aqueous phase for a prolonged period → long duration of action (12–24 hours).
- Slow clearance from CSF allows rostral spread — cephalad migration toward the brainstem. This is the mechanism for delayed respiratory depression (6–18 hours post-injection), a hallmark of epidural morphine.
4. Systemic Vascular Absorption
- Concurrent absorption into the epidural venous plexus occurs, with peak plasma levels at ~15–30 min after epidural dosing.
- Systemic plasma levels are lower than after equivalent IV/IM doses, but measurable.
- This vascular absorption contributes a supraspinal component to analgesia.
5. Metabolism and Elimination
- Hepatic glucuronidation → morphine-3-glucuronide (M3G, inactive/antagonistic) and morphine-6-glucuronide (M6G, active analgesic, crosses blood-brain barrier).
- Elimination half-life: ~2–3 hours (plasma); CSF clearance is much slower.
- Renal excretion of glucuronides; accumulation of M6G in renal failure.
DepoDur (Extended-Release Epidural Morphine):
- Uses DepoFoam multivesicular lipid particles to slow release.
- Smaller peak plasma concentration; peak absorption delayed vs. plain epidural morphine.
- Duration of action extended to 24–48 hours from a single 5–15 mg dose.
- Alters pharmacokinetics if preceded by large-dose epidural lidocaine.
— Miller's Anesthesia 10e, p. 2853–2856; Barash 9e, p. 4697–4699
A.3 Pharmacodynamics of Epidural Morphine [4 marks]
Mechanism of Analgesia
Epidural morphine produces analgesia via two complementary mechanisms:
1. Spinal (Primary) Mechanism
- Morphine diffuses across the dura into the CSF → reaches dorsal horn of the spinal cord (substantia gelatinosa, laminae I and II).
- Binds μ-opioid receptors (MOR) on presynaptic primary afferent terminals → inhibits release of substance P and glutamate.
- Postsynaptic MOR activation → hyperpolarisation via ↑K⁺ conductance and ↓Ca²⁺ conductance → reduced nociceptive transmission.
- Because morphine is hydrophilic, it provides wide dermatomal spread (segmental and intersegmental analgesia) — not confined to the level of injection.
- Produces analgesia without sympatholysis or motor blockade (unlike local anaesthetics).
2. Supraspinal Mechanism (Secondary)
- Systemic vascular absorption carries morphine to periaqueductal grey (PAG), nucleus raphe magnus, and locus coeruleus.
- Activates descending inhibitory pathways (serotonergic, noradrenergic) → amplifies spinal analgesia.
- This supraspinal component is responsible for some of the side effects (nausea, sedation).
Comparison: Hydrophilic vs. Lipophilic Epidural Opioids
| Property | Morphine (Hydrophilic) | Fentanyl (Lipophilic) |
|---|---|---|
| Onset | Slow (30–60 min) | Fast (5–15 min) |
| Duration | Long (12–24 h) | Short (2–4 h) |
| Spread | Wide dermatomal | Segmental only |
| Primary action | Spinal | Supraspinal (systemic uptake) |
| Rostral spread | Yes (↑risk late respiratory depression) | Minimal |
Pharmacodynamic Effects
| System | Effect |
|---|---|
| Analgesia | Potent, long-duration; effective for labour, postoperative, cancer pain |
| Respiratory | Early respiratory depression (1–2 h, vascular absorption) + delayed respiratory depression (6–18 h, rostral CSF spread to brainstem respiratory centres) — the most feared complication |
| Pruritus | Most common side effect (~30–60%); due to μ-receptor activation in dorsal horn and trigeminal nucleus; treated with low-dose naloxone or nalbuphine |
| Nausea/Vomiting | Activation of chemoreceptor trigger zone (CTZ) via supraspinal uptake |
| Urinary retention | Inhibition of sacral parasympathetic outflow (S2–S4); μ-receptor activation in spinal cord → detrusor relaxation |
| Sedation | Supraspinal effect; dose-dependent |
| Cardiovascular | Minimal direct effect; no sympatholysis (unlike epidural LA) |
Clinical Applications of Epidural Morphine
- Labour analgesia (combined with LA, e.g., bupivacaine 0.1% + morphine or fentanyl)
- Post-caesarean section (intrathecal 0.1–0.2 mg or epidural 3–5 mg single shot)
- Major abdominal, thoracic, orthopaedic surgery — part of multimodal analgesia
- Cancer pain — long-term epidural infusions
- Contraindication to concurrent systemic opioid PCA (additive respiratory depression)
Monitoring Requirements
Patients receiving epidural morphine require monitoring for delayed respiratory depression up to 24 hours — respiratory rate, oxygen saturation, sedation scoring (Ramsey/RASS).
— Barash's Clinical Anesthesia 9e, p. 4696–4699; Miller's Anesthesia 10e, p. 2849–2856; Sabiston Surgery p. 355
The image provided only shows Question 1 from MAY 24 Paper 1. Please share the remaining two questions (Questions 2 and 3) and I will answer them with the same level of detail for your MD Anaesthesiology exam.
This is a shared conversation. Sign in to Orris to start your own chat.